Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung CancerPrimo N. Lara, Giorgio V. Scagliotti, Jean‐Yves Douillard et al.|Journal of Clinical Oncology|2011Cited by 320
Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndromePrimo N. Lara, Theodore Wun, Tracy L Coe et al.|The American Journal of Medicine|1999Cited by 106
Identification of a bladder cancer-specific ligand using a combinatorial chemistry approachHongyong Zhang, Chong-xian Pan, Christopher P. Evans et al.|Urologic Oncology Seminars and Original Investigations|2010Cited by 53
Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107Przemyslaw Twardowski, Primo N. Lara, Catherine M. Tangen et al.|Kidney Cancer|2017Cited by 41
An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancerDaniel Morgensztern, Pilar Garrido, Nina Karaseva et al.|Lung Cancer|2019Cited by 24